Modality
Cell Therapy
MOA
ALKi
Target
BET
Pathway
Proteasome
PsAFSGSNB
Development Pipeline
Preclinical
May 2023
→ Feb 2027
PreclinicalCurrent
NCT08519644
287 pts·FSGS
2024-07→2027-02·Not yet recruiting
NCT05782308
2,315 pts·NB
2023-05→TBD·Recruiting
2,602 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-1310mo awayInterim· FSGS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2027-02-13 · 10mo away
FSGS
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08519644 | Preclinical | FSGS | Not yet recr... | 287 | 6MWD |
| NCT05782308 | Preclinical | NB | Recruiting | 2315 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |